相关实验视频

Updated: Jul 16, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

在非小细胞肺癌中EGFR exon20插入突变:临床影响和针对性治疗的最新进展

Qianming Bai¹, Jialei Wang², Xiaoyan Zhou¹

¹Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Institute of Pathology, Fudan University, Shanghai, China.

Cancer treatment reviews

|September 13, 2023

概括

在非小细胞肺癌 (NSCLC) 中表皮生长因子受体 (EGFR) 插入20个外显子 (ex20ins) 显示对标准疗法的反应不佳. 针对这些突变的新型治疗方法为改善患者的治疗结果提供了有前途的治疗选择.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

向疗法已经改变了非小细胞肺癌 (NSCLC) 治疗.
表皮生长因子受体 (EGFR) 突变是NSCLC中关键的瘤驱动因素.
EGFR外因子20插入 (ex20ins) 与经批准的EGFR-氨酸激酶抑制剂 (EGFR-TKI) 的反应不佳有关.

研究的目的:

审查EGFR ex20ins突变的结构和分子特征.
总结 EGFR ex20ins. 的当前诊断策略.
为患有EGFR ex20ins的NSCLC患者提供已批准和新兴疗法的概述.

主要方法:

对结构,分子和临床数据的文献综述.
对诊断检测策略的分析.
现有和新型疗法临床试验结果的摘要.

主要成果:

EGFR ex20ins突变具有独特的结构和分子特性.
诊断方法正在发展,以精确识别ex20ins.
新兴疗法,包括新型EGFR-TKI和双特异性抗体,显示出潜力.

结论:

EGFR ex20ins突变代表了一个独特的NSCLC子集,其治疗需求尚未得到满足.
较新的向药物和治疗策略对于治疗EGFR ex20ins. ex20ins. 的NSCLC至关重要.
了解反应异质性和耐药性机制对于未来的治疗开发至关重要.

关键词:

在前面和后面的朋友.欧洲农业基金的技术技能.在Exon20中,Exon20是什么?插入突变是一种插入突变.莫博塞尔提尼布 (Mobocertinib) 是一种药物.非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.

更多相关视频

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...